Novartis AG agreed to pay more than $729 million to settle U.S. government charges that the company paid illegal kickbacks to doctors and patients to boost drug sales, the U.S. Department of Justice said.
Regeneron Pharmaceuticals said the company will vigorously defend federal charges of being involved in a kickback scheme to bolster sales of the blockbuster macular degeneration drug Eylea.
A Harvard professor arrested earlier this year for failing to disclose ties to China’s Thousand Talents Program was indicted for making false statements to federal authorities regarding that work in Wuhan, China.
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
The Department of Justice leveled more charges against members of the U.S. science community who have alleged ties to China.
CVS Health Corp. and the drugstore chain’s Omnicare unit were sued by the U.S. government, which accused them of fraudulently billing Medicare and other programs for drugs for older and disabled people without valid prescriptions.
Over the past 50 years, the FDA has relied upon – and often deferred to – industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
U.S. prosecutors announced criminal charges accusing the founders of Outcome Health of overseeing a scheme to overbill clients and fraudulently obtain nearly $1 billion of funds, including from major investors.
Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.
Fagron Holding USA LLC will pay $22.5 million to resolve allegations that the pharmaceutical supplier’s subsidiaries inflated average wholesale prices for compound drug ingredients and submitted fraudulent claims to federal healthcare programs, the U.S. Department of Justice said.